Skip to content

News and
Events

Sort By
  • Newest
  • Oldest
  • A to Z
  • Z to A
Nov 15 2015
GrayBug Announces Presentation at the OIS@AAO Drug Delivery Company Showcase
GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, said that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present a brief corporate overview at the Drug Delivery Company Showcase...
Read More
Aug 5 2015
Aerie Pharmaceuticals and GrayBug Announce Research Collaboration
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular...
Read More
Mar 9 2015
GrayBug Raises $1.74 Million in Series A2 Financing
Proceeds to support development of lead compound GB-102 Christy Shaffer, Ph.D., appointed Chair of the Board March 9, 2015 – GrayBug, Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced the closing of a $1.74 million Series A2...
Read More
Apr 17 2014
GrayBug appoints Dr. Gerald Cagle and Dr. Jeffrey Cleland to its Board of Directors
Ophthalmology Industry Pioneers with Expertise in Product Development and Extended Release Protein Drug Delivery Join GrayBug Board BALTIMORE, MD (XXX April, 2014) -­‐ GrayBug, LLC, a company developing a continuum of proprietary controlled-­‐release drug delivery technologies for strategic partnership and its own therapeutic products for major ocular diseases announced today...
Read More
Jan 9 2014
GrayBug to Present at the 6th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research
January 9, 2014 – GrayBug is pleased to announce that it has been invited to present at the 6th Annual conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR) at the Beckman Center of the National Academies of Science and Engineering on January 23-25, 2014, in Irvine,...
Read More
Apr 11 2012
GrayBug Secures Worldwide Rights to Develop Proprietary Ophthalmic Drug Delivery Platforms
GrayBug raises $1mm from investors and is awarded a $200k grant to support research Baltimore, MD – April 11, 2012 – GrayBug LLC announced today they have raised over $1 million in equity from investors and have successfully obtained the worldwide right to new technologies invented by GrayBug LLC co-founders...
Read More
1 2 5 6